Clinical Trial Update: A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) [Phase 3]

View source ↗

Summary

Phase 3 study EMERGENT-2 evaluating KarXT for acutely psychotic hospitalized adults with schizophrenia has completed; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychosis
• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia, Schizophrenia; Psychosis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-12